Suppr超能文献

靶向蛋白降解技术在 G 蛋白偶联受体中的应用。

The application of targeted protein degradation technologies to G protein-coupled receptors.

机构信息

Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.

Medicinal Chemistry Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville, 3052, Victoria, Australia.

出版信息

Br J Pharmacol. 2024 Jul;181(14):2351-2358. doi: 10.1111/bph.16079. Epub 2023 Apr 20.

Abstract

The ubiquitin-proteasome system is one of the major pathways for the degradation of cellular proteins. In recent years, methods have been developed to exploit the ubiquitin-proteasome system to artificially degrade target proteins. Targeted protein degraders are extremely useful as biological tools for discovery research. They have also been developed as novel therapeutics with several targeted protein degraders currently in clinical trials. However, almost all targeted protein degrader technologies have been developed for cytosolic proteins. The G protein-coupled receptor (GPCR) superfamily is one of the most important classes of drug targets, yet only limited examples of GPCR degradation exist. Here, we review these examples and provide a perspective on the different strategies that have been used to apply targeted protein degradation to GPCRs. We also discuss whether alternative approaches that have been used to degrade other integral membrane proteins could be applied to the degradation of GPCRs. LINKED ARTICLES: This article is part of a themed issue Therapeutic Targeting of G Protein-Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc.

摘要

泛素-蛋白酶体系统是细胞内蛋白质降解的主要途径之一。近年来,已经开发出利用泛素-蛋白酶体系统人为降解靶蛋白的方法。靶向蛋白降解剂作为发现研究的生物工具非常有用。它们也已被开发为新型治疗药物,目前有几种靶向蛋白降解剂正在临床试验中。然而,几乎所有的靶向蛋白降解技术都是针对细胞质蛋白开发的。G 蛋白偶联受体(GPCR)超家族是最重要的药物靶点之一,但仅存在有限的 GPCR 降解的例子。在这里,我们回顾了这些例子,并对应用靶向蛋白降解技术于 GPCR 的不同策略提供了一个视角。我们还讨论了是否可以将已用于降解其他整合膜蛋白的替代方法应用于 GPCR 的降解。

相关文章

本文是治疗性靶向 G 蛋白偶联受体:2021 年澳大拉西亚临床和实验药理学和毒理学学会虚拟年会热点话题特刊的一部分。要查看本节中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验